C4 Therapeutics Inc is trading 5.7% up at $4.09 following the presentation of positive Phase 1 data for cemsidomide at the EHA Congress.
- The trial for relapsed/refractory multiple myeloma demonstrated a 53% overall response rate and a favorable safety profile.
- Shares are extending a sharp weekly rebound from levels below $3.60 as investors reprice the clinical catalyst.